EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Erythrocyte Methotrexate–Polyglutamate Concentrations in Pediatric Inflammatory Bowel Disease

Eva Vermeer iD, Eduard A Struys iD, Marry Lin iD, Johan E van Limbergen iD, Nanne K H de Boer iD, Maja Bulatović-Ćalasan iD, Tim G J de Meij iD, Robert de Jonge iD

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izaf035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Eva Vermeer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Gastroenterology, Emma Children's Hospital, Amsterdam University Medical Centre, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Methotrexate, Polyglutamic Acid, Erythrocytes, Drug Monitoring. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Therapeutic drug monitoring (TDM) of methotrexate (MTX) is challenging due to its pharmacokinetics and short plasma half-life. Intracellular MTX–polyglutamates (PG1–5), which accumulate over time, have not been assessed in pediatric inflammatory bowel disease (IBD). This study aimed to evaluate erythrocyte MTX-PG as a potential TDM tool in pediatric IBD.

Methods

In this cross-sectional study, MTX-PG concentrations were measured in erythrocytes of children with IBD on stable low-dose MTX for at least 12 weeks using stable-isotope dilution liquid chromatography–tandem mass spectrometry. The influence of administration route, MTX dosage, and anthropometrics on MTX-PG concentrations was examined.

Results

Seventy-eight patients were included, showing MTX-PG3 as the predominant subspecies (median 27.0 nmol/L) with a median MTX-PGtotal of 74.8 nmol/L. A higher MTX dose correlated significantly with elevated levels of MTX-PG3, MTX-PG4, MTX-PG5, and MTX-PGtotal (P < .01). Adjusted for body surface area, MTX dose remained significantly associated with higher MTX-PG concentrations (P < .01). However, comparison by administration route was limited due to a few patients on subcutaneous MTX (n = 4).

Conclusions

We observed high interindividual variability in the reached erythrocyte MTX-PG concentrations. Body surface adjusted or unadjusted MTX dosage showed a positive linear correlation with erythrocyte MTX-PG concentrations in children with IBD. This is a prerequisite for TDM and provides a strong basis for further research into the relation between TDM of MTX, efficacy, and toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexatePolyglutamic AcidErythrocytesDrug MonitoringInflammatory Bowel DiseasesImmunosuppressive AgentsHumansFemaleMaleCross-Sectional StudiesChildAdolescentChild, PreschoolTandem Mass Spectrometry

Stichwörter der Autor:innen

Crohn’s diseasemethotrexatepediatric inflammatory bowel diseasetherapeutic drug monitoringulcerative colitis

Substanzen

MethotrexatePolyglutamic Acidmethotrexate polyglutamateImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Paediatric Gastroenterology, Emma Children's Hospital, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
  • Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
  • Amsterdam Reproduction & Development (AR&D) Research Institute, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
  • Laboratory of Specialised Diagnostics and Research, Department of Laboratory Medicine, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
  • Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
  • Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.

ORCID-Profile: Eva Vermeer, Eduard A Struys, Marry Lin, Johan E van Limbergen, Nanne K H de Boer, Maja Bulatović-Ćalasan, Tim G J de Meij, Robert de Jonge

Zitieren

APA

Vermeer, E., Struys, E. A., Lin, M., van Limbergen, J. E., de Boer, N. K. H., Bulatović-Ćalasan, M., de Meij, T. G. J., & de Jonge, R. (2025). Erythrocyte Methotrexate–Polyglutamate Concentrations in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf035

Vancouver

Vermeer E, Struys EA, Lin M, van Limbergen JE, de Boer NKH, Bulatović-Ćalasan M, et al. Erythrocyte Methotrexate–Polyglutamate Concentrations in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf035

BibTeX
@article{Vermeer2025,
  author = {Vermeer, Eva and Struys, Eduard A and Lin, Marry and van Limbergen, Johan E and de Boer, Nanne K H and Bulatović-Ćalasan, Maja and de Meij, Tim G J and de Jonge, Robert},
  title = {Erythrocyte Methotrexate–Polyglutamate Concentrations in Pediatric Inflammatory Bowel Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izaf035}
}
Kostenlos starten →